ABCELLERA BIOLOGICS INC
ABCLNASDAQ🏆 #1591 by market capEarnings Nov 5US Equity
$10.04▲ $0.29 (+2.87%)
Live1h▲ 0.9%
24h▲ 2.9%
7d▲ 69.2%
14d▲ 85.9%
30d▲ 54.2%
1y▲ 135.7%
🏦Market Cap
$3.07B
Small Cap
📈Revenue Growth (YoY)
+160.6%
High Growth
📊Gross Margin
75.0%
High
💵FCF Margin
-271.2%
Thin
⚖️P/S Ratio
45.0x
Expensive
Otter Score
54
Weak
📊
Analyst Ratings
Price
$10.04
Total
12
Raised
1
Lowered
1
Avg PT
$15.33
H / L
$30 / $7
| Institution | Action | Rating | Date |
|---|---|---|---|
Stifel | Reiterated | Buy | 2026-08-06 |
Cantor Fitzgerald | Reiterated | Overweight | 2026-08-06 |
Benchmark | Upgraded | Hold → Buy | 2026-07-07 |
Leerink Partners | Downgraded | Outperform → Market Perform | 2025-11-07 |
Keybanc | Reiterated | Overweight | 2025-07-14 |
Truist Securities | Reiterated | Buy | 2025-05-16 |
Goldman Sachs | Reiterated | Buy | 2023-08-04 |
Credit Suisse | Reiterated | Outperform | 2023-05-05 |
Cowen & Co. | Reiterated | Outperform | 2023-02-28 |
BMO Capital | Reiterated | Outperform | 2023-02-22 |
SVB Leerink | Reiterated | Outperform | 2023-01-06 |
Piper Sandler | Reiterated | Overweight | 2022-07-26 |
One row per institution, most recent rating